Progress Toward Commercial Scale and Efficiency in Cell Therapy Bioprocessing

About the Whitepaper

At the time of writing there are 672 cell and gene therapy companies worldwide and 20 products approved by the food and drug administration (FDA). Dendreon's Provenge autologous cell therapy although approved by the FDA ultimately failed commercially due to a manufacturing and distribution model that was not efficient.

Cost of Goods (CoGs), manufacturing process and logistics are critical to the success of cell therapy commercialisation and these need to be considered from the inception of a cell therapy company in addition to the clinical science. Three key enablers for success are manufacturing automation/ single use technologies, a diverse pipeline in modularised facilities, and sophisticated data acquisition/ logistics.

This whitepaper explores the ways that progress towards commercial scale and efficiency in cell therapy bioprocessing is happening.

About the author:David Orchard-Webb, PhD, is a bioscience consultant currently serving as a research assistant for Professor Amine Kamen in the Department of Bioengineering at McGill University in Montreal, Quebec, Canada.

September 25 - 28, 2017
Hynes Convention Center,
Boston, MA

Cell & Gene Therapy Bioprocessing & Commercialization

September 25 - 28, 2017
Hynes Convention Center,
Boston, MA

Download Whitepaper

CONTINUE

Terms and Conditions  |  Privacy Policy

† You may still receive emails from us regarding any current registrations or orders.

Fix the following errors:
Hide